Leaders of the Congressional Artificial Intelligence Caucus introduced a bill that would create a National Artificial Intelligence Research Resource (NAIRR) to provide AI-related resources to spur innovation and US competitiveness. Mintz Antitrust Practice Co-chair Bruce Sokler and ML Strategies’ Alex Hecht and Christian Fjeld discuss the bill and the three-year push for the NAIRR.

Read the latest edition of AI: The Washington Report, a joint undertaking of Mintz and ML Strategies covering potential federal legislative, executive, and regulatory activities related to AI, including the White House’s voluntary framework for ensuring safe, secure, and trustworthy AI.

Read the latest edition of AI: The Washington Report, a joint undertaking of Mintz and ML Strategies covering potential federal legislative, executive, and regulatory activities related to AI, including the FTC’s enforcement actions and guidance related to AI.

Read the latest edition of AI: The Washington Report, a joint undertaking of Mintz and ML Strategies covering potential federal legislative, executive, and regulatory activities related to AI, including the newly introduced National AI Commission Act that seeks to establish a commission to formulate a legislative framework on AI.

The accelerating advances in AI have heightened legislative, executive, and regulatory activities focused on its implications. In a series of articles, Mintz and ML Strategies explore the federal government’s actions in this area, such as the national AI strategic plan and upcoming US Senate forums aimed at forging consensus and informing future legislation.

Read the second edition of AI: The Washington Report, a joint undertaking of Mintz and ML Strategies covering potential federal legislative, executive, or regulatory activities related to AI.

Read the inaugural issue of AI: The Washington Report, a joint undertaking of Mintz and ML Strategies covering potential federal legislative, executive, or regulatory activities related to AI.

The next three weeks will be full of activity in Washington D.C., as the House of Representatives and Senate are working to push their legislative agendas to garner support from their constituents ahead of an August recess and before political “silly season” officially kicks in ahead of the upcoming mid-term elections in November. Here’s our latest update on what you can expect in Congress during the July work period.

Anyone who has spent any time around health care policymaking circles in Washington, D.C. has heard about the intense five-year cycle Congress goes through in order to reauthorize the biggest user fee programs at the Food and Drug Administration (FDA). Mintz previously published this wonderful explanation of the process complete with an estimated timeline for how this year’s reauthorization was likely to go. As a reminder, the current authorization for FDA’s various human product user fee programs – with the exception of the over-the-counter drug program that was freshly created in 2020 – will expire on September 30, 2022 with the end of the federal government’s fiscal year, unless they are renewed by Congress before that time.

Over the past year, the demand for health care via telehealth has continued to skyrocket as a result of the COVID-19 pandemic and the public’s increased comfort with obtaining health care goods and services virtually. Join Ellen Janos, Karen Lovitch, Kate Stewart and Alex Hecht as they demystify the current status of laws and regulations, untangle the web of legislation before Congress related to the expansion of telehealth services, discuss recent enforcement activity, and look ahead to trends we see on the horizon.